Solid Biosciences Inc (NAS:SLDB)

$ 9.12 0.17 (1.9%) Market Cap: 350.02 Mil Enterprise Value: 163.25 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 40/100

Solid Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Solid Biosciences Inc at Citi BioPharma Conference Transcript
Sep 07, 2023
Solid Biosciences Inc at Barclays Virtual Gene Editing & Therapy Summit Transcript
May 24, 2023
Solid Biosciences Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Solid Biosciences Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Apr 24, 2023
Solid Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Solid Biosciences Inc at BMO Capital Markets BioPharma Spotlight Series: Genetic Medicine Delivery (Virtual) Transcript
Mar 28, 2023
Solid Biosciences Inc at Barclays Global Healthcare Conference Transcript
Mar 14, 2023
Solid Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Solid Biosciences Inc To Acquire Aavantibio Inc Call Transcript
Sep 30, 2022
Q1 2022 Solid Biosciences Inc Earnings Call Transcript
Apr 27, 2022

$9.65 (-16.98%)

Earnings
Solid Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Solid Biosciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 28, 2021
Solid Biosciences Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
Q1 2021 Solid Biosciences Inc Earnings Call Transcript
May 14, 2021

$52.35 (-21.40%)

Earnings
Pfizer Inc, Avidity Biosciences, Sarepta Therapeutics, Solid Biosciences, and Ultragenyx Pharmaceutical at Guggenheim Partners Healthcare Talks: Genomic Medicines & Rare Disease (Virtual) Transcript
Apr 01, 2021
Solid Biosciences Inc. - Special Call Transcript
Mar 15, 2021
Solid Biosciences Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
Solid Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q3 2020 Solid Biosciences Inc Earnings Call Transcript
Nov 05, 2020

$48.6

Earnings
Solid Biosciences Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Solid Biosciences Inc. - Special Call Transcript
Dec 18, 2019
Solid Biosciences Inc. - Special Call Transcript
Nov 12, 2019

Solid Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 07:55PM GMT

Release Date Price: $5 (-5.66%)

Transcript 10-K

Huidong Wang

Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang. I'm SMID cap biotech analyst at the Barclays. So welcome to our Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Solid Biosciences. With me, we have Bo Cumbo, President and Chief Executive Officer. And Bo, maybe you start with a little bit overview of the company, and we can dive into the questions.

Alexander G. Cumbo

Solid Biosciences Inc. - President, CEO & Director

Great. Thank you. First of all, thank you, Gena, for the invitation to the conference, and thank you, Barclays. I'm Bo Cumbo, CEO of Solid Biosciences. Solid is a precision genetic medicine company, focused mainly on neuromuscular and cardiomyopathies. Solid purchased a company called AavantiBio, closed on this on December 2, 2022. I came from AavantiBio as the CEO of AavantiBio myself and my management team moved over into Solid Biosciences.

We focus on Duchenne muscular dystrophy, as our lead drug, followed by Friedreich's

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.